Status:
COMPLETED
Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease
Lead Sponsor:
Zagazig University
Collaborating Sponsors:
Suez University
Benha University
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
18+ years
Brief Summary
The work investigate the role of fetuin-A in the diagnosis and assessment of the severity of non-alcoholic fatty liver disease (NAFLD).
Detailed Description
The prevalence of nonalcoholic fatty liver disease (NAFLD), which has recently become one of the most prevalent chronic liver illnesses, is about 25% worldwide. NAFLD is a progressive liver disease th...
Eligibility Criteria
Inclusion
- patients who were admitted to the university hospitals with inclusion criteria
Exclusion
- Patients who are younger than 18 years old,
- Patients with a history of high alcohol consumption (more than 40 g/day for men and 20 g/day for women) over the previous five years,
- Patients who have concurrent hepatitis B and hepatitis C viral infections
- Patients with hepatobiliary malignancy, Wilson's disease, alpha-one antitrypsin deficiency, and autoimmune hepatitis,
- Pregnant women
- Patients who take steatogenic pharmaceuticals including amiodarone, valproic acid, antiretrovirals, methotrexate, and tetracyclines, or NAFLD treatments like vitamin E, metformin, and thiazolidinediones
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 20 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06097039
Start Date
January 1 2023
End Date
February 20 2024
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University
Zagazig, Sharqia Province, Egypt, 44511